mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
In 2015, she was a laureate of the L'Oréal-UNESCO For Women in Science Awards "for her groundbreaking work in macromolecular mass spectrometry and pioneering gas phase structural biology by probing the structure and reactivity of single proteins and protein complexes, including membrane proteins." In 2017, she was elected a Foreign Associate of the US National Academy of Sciences. In 2018, she won the Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society. In 2019, she won the Novozymes Prize for "almost single-handedly founding a subfield of mass spectrometry proteomics". Also in 2019 she received the Royal Medal. In 2020, she was chosen as the recipient of the Othmer Gold Medal. In 2021, she received the 2022 Louis-Jeantet Prize for Medicine. and the 2022 European Chemistry Gold Medal by the European Chemical Society. Also in 2021, she became an International Honorary Member of the American Academy of Arts and Sciences. In 2022, she was awarded the Franklin Institute Award for Chemistry. In 2023, she was elected to the American Philosophical Society and was awarded the John B. Fenn Award for Distinguished Contribution to Mass Spectrometry. She was named one of the top ten "Innovators and Trailbalzers" on the 2023 Power List by the Analytical Scientist. In 2024, she received the EPO European Inventor Lifetime Achievement Award for her work in mass spectrometry that significantly advanced biochemical research and medical diagnostics.
On January 3, 2020, Cold Stone Creamery announced that it would close its doors on January 31, 2020, in Singapore. In March 2015, Cold Stone opened its first location in Turkey's capital Ankara. In 2015 Cold Stone Creamery opened its first location in El Salvador in Multiplaza Mall and in April 2023, Cold Stone opened its first United Kingdom location in Charing Cross Road. In May 2007, Cold Stone Creamery merged with Kahala Corp to form Kahala-Cold Stone, which collectively owns 8 brands. Doug Ducey, who had served as president and CEO of Cold Stone Creamery since 1995, and future Governor of Arizona, was named CEO of the new company. Kevin Blackwell, the former CEO of Kahala, became chairman of the board and chief strategist. However, in September 2007, Ducey announced he was leaving the company. Blackwell was named CEO. In 2013, the Serruya family, based in Toronto, Ontario, purchased a majority interest in Kahala and changed the name to Kahala Brands to better align with the focus of the business. After a decade of operation, Cold Stone Creamery closed all its outlets in Singapore on January 31, 2020.
== Background == Opioids are a diverse class of strong, addictive, and inexpensive drugs, which include opiates (i.e., morphine and codeine), oxycodone (OxyContin, Percocet), hydrocodone (Vicodin, Norco), and fentanyl. Traditionally, opioids have been prescribed for short-term pain management, as short-term use is supported by a body of evidence. The usefulness of opioids in chronic pain is dependent on the kind of pain being treated (e.g., visceral and central pain may be "especially unresponsive to long-term opioid therapy") and the patient. Clinical guidelines advise that opioids should only be used for chronic pain if safer alternatives are not feasible, as their risks often outweigh their benefits. The potency and availability of opioids have made them popular as both medical treatments and recreational drugs. The Substance Abuse and Mental Health Services Administration (SAMHSA) estimated that over 10 million Americans abused prescription opioids in 2018; 47,600 Americans died from opioid overdoses in 2018. These substances have high risks of addiction and overdose, and long-term use can cause tolerance and physical dependence. SAMHSA allocated $7.5 billion between January 2016 and June 2020, as response to this opioid crisis. These resources aim to increase access to medications for treatment, reduce overdose deaths, and sustain prevention and recovery. When people continue to use opioid medications beyond what a doctor prescribes, whether to minimize pain or induce euphoric feelings, it can mark the beginning stages of an opioid addiction.
=== Analgesia === Dextropropoxyphene is generally considered a weak analgesic, with several studies finding its efficacy is no better than acetaminophen. Like codeine, it is a weak opioid. However, dextropropoxyphene has one-third to one-half of the analgesic activity of codeine.
=== Melanoma === For high-risk melanoma, it is used as an adjuvant therapy to surgery in some countries. It was first approved for the purpose by FDA on 29 March 2011, based on a single phase III trial. The usage remains controversial — frequency of severe side-effects is high, overall survival benefits substantially vary across different trials, and there is no consensus on the dosage regimen. Meta-analyses have suggested that the drug might be more helpful for patients with ulcerated primary lesion.
Sources: en.wikipedia.org
=== Environmental pollution === Considering the complex interactions between humans, animals and the environment, it is also important to consider the environmental aspects and contributors to antimicrobial resistance. One of these factors is human and hospital waste, which is a substantial contributor to environmental antimicrobial resistance (AMR). It is estimated that around 50–80% of antibiotics are passed unmetabolized in urine and 4–30% in feces, causing large quantities of active antibiotics to enter sewage systems. Sewage environments contain high levels of antimicrobial-resistant bacteria (ARB), antimicrobial resistance genes (ARGs), and mobile genetic elements such as plasmids, which enable rapid gene exchange. Wastewater treatment plants (WWTPs) are typically not designed to remove AMR; in some cases, multidrug-resistant species such as Escherichia, Shigella, and Klebsiella can increase twofold in treated wastewater. Methicillin-resistant Staphylococcus aureus (MRSA) has also been detected in both raw and treated sewage. Agriculture is also a major contributor to environmental AMR. Manure from livestock (such as cattle, sheep, etc.) contains residual antibiotics, which enter the soil as farmers usually use it as fertilizer. These are typically at levels of 1–10 mg/kg, and also contain ARBs and ARGs. One megaton of antibiotics has been estimated to have entered global soils through manure application. Pathogens can survive in soil for up to 10 years and on plant surfaces for up to 1 year, thereby enabling long-term environmental continuation of AMR.
=== 1930s === The 1930s was a huge era for biomedical research, as this was the era where antibiotics became more widespread and vaccines started to be developed. In 1935, the idea of a polio vaccine was introduced by Dr. Maurice Brodie. Brodie prepared a died poliomyelitis vaccine, which he then tested on chimpanzees, himself, and several children. Brodie's vaccine trials went poorly since the polio-virus became active in many of the human test subjects. Many subjects had fatal side effects, paralyzing, and causing death.
=== Factors === There are some factors that are closely related to the selectivity property of antimicrobial peptides, among which the cationic property contributes most. Since the surface of the bacterial membranes is more negatively charged than mammalian cells, antimicrobial peptides will show different affinities towards the bacterial membranes and mammalian cell membranes. In addition, there are also other factors that will affect the selectivity. It's well known that cholesterol is normally widely distributed in the mammalian cell membranes as a membrane stabilizing agent but absent in bacterial cell membranes (except when sequestered by H. pylori); and the presence of these cholesterols will also generally reduce the activities of the antimicrobial peptides, due either to stabilization of the lipid bilayer or to interactions between cholesterol and the peptide. So the cholesterol in mammalian cells will protect the cells from attack by the antimicrobial peptides. Besides, the transmembrane potential is well known to affect peptide-lipid interactions. There's an inside-negative transmembrane potential existing from the outer leaflet to the inner leaflet of the cell membranes and this inside-negative transmembrane potential will facilitate membrane permeabilization probably by facilitating the insertion of positively charged peptides into membranes. By comparison, the transmembrane potential of bacterial cells is more negative than that of normal mammalian cells, so bacterial membrane will be prone to be attacked by the positively charged antimicrobial peptides.
Short proteins can be synthesized chemically by a family of peptide synthesis methods. These rely on organic synthesis techniques such as chemical ligation to produce peptides in high yield. Chemical synthesis allows for the introduction of non-natural amino acids into polypeptide chains, such as attachment of fluorescent probes to amino acid side chains, (this can also be achieved via genetic engineering when producing recombinant proteins). These methods are useful in laboratory biochemistry and cell biology, though generally not for commercial applications. Chemical synthesis is inefficient for polypeptides longer than about 300 amino acids, and the synthesized proteins may not readily assume their native tertiary structure. Most chemical synthesis methods proceed from C-terminus to N-terminus, opposite the biological reaction.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.